Oppenheimer & Co’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Oppenheimer & Co’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9	Closed	-$15K	–	1584
2021 Q1	$15K	Buy	+9	New	+$18K	﹤0.01%	1428

Other funds holding BXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Oppenheimer & Co's BXRX Position: Q2 2021 in Review

Oppenheimer & Co sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2021, closing a stake of 9 shares — an estimated $15K sold.

Oppenheimer & Co first reported a position in BXRX in Q1 2021 and held it in 1 quarter. The position peaked at $15K in Q1 2021. 31 funds tracked by Wall St. Rank hold BXRX as of Q2 2021.

Oppenheimer & Co reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Oppenheimer & Co sold 9 Baudax Bio, Inc. Common Stock shares in Q2 2021, an estimated $15K.
Oppenheimer & Co first reported a position in Baudax Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
Oppenheimer & Co's Baudax Bio, Inc. Common Stock position peaked at $15K in Q1 2021.
31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2021.

Based on Oppenheimer & Co's 13F filing for Q2 2021, filed 3 Aug 2021.